FX.co ★ Arvinas, Pfizer Report Positive Data From Phase 1b Study Of Vepdegestrant Combination Therapy

Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) have announced preliminary results from the Phase 1b segment of the TACTIVE-U sub-study, which investigates the use of Vepdegestrant in conjunction with Abemaciclib for patients with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.

The study revealed that administering Abemaciclib at 150 mg twice daily alongside the recommended Phase 3 monotherapy dose of 200 mg of Vepdegestrant once daily was both safe and well-tolerated by participants. Importantly, no significant drug-drug interactions were observed, and there were no clinically meaningful impacts on Abemaciclib exposure.

The combination therapy also showed promising results with a clinical benefit rate of 62.5% and an overall response rate of 26.7% in patients who had prior treatment with a CDK4/6 inhibitor.

In financial news, Arvinas’s stock has dropped by 1.75% to $24.64 on the Nasdaq, while Pfizer's shares are down 1.13%, currently trading at $25.81 on the New York Stock Exchange.